argenx SE (ARGX) Stock Price, Financials & Summary

Price chart

Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

Open$839.19

From 52W high−22.64%

Volume388972.00

Market cap$51.51B

P/E (TTM)38.7x

P/S (TTM)12.4x

Div yield—

Key dataOct 16, 2026

Open

$839.19

From 52W high

−22.64%

Volume

388972.00

Market cap

$51.51B

ValuationView details →

P/E (Fwd)

101.0x

EV/EBITDA

35.4x

P/E (TTM)

38.7x

RSI (14)

32.2

MomentumView details →

1D Return

−3.21%

YTD Return

−3.10%

SummaryUpdated Jun 1, 2026

argenx SE (NASDAQ:ARGX) is a Dutch biotechnology company founded in 2008 and headquartered in Amsterdam, Netherlands. The company went public on NASDAQ in May 2017. argenx has evolved from a research-stage biotechnology company into a commercial-stage biopharmaceutical company with its flagship product VYVGART achieving significant commercial success. The company specializes in developing antibody-based therapies for autoimmune diseases, with a particular focus on conditions affecting the neuromuscular system. argenx has established itself as a leader in targeting the neonatal Fc receptor (FcRn) pathway, a novel mechanism for treating antibody-mediated autoimmune diseases.

Ask drillr about argenx SE →

ValuationView details →

P/E (Fwd)

101.0x

P/E (TTM)

38.7x

EV/EBITDA

35.4x

EV/Sales

11.2x

P/S (TTM)

12.4x

P/B (TTM)

6.1x

ProfitabilityView details →

Gross Margin

89.15%

Net Margin

31.11%

EBITDA Margin

31.56%

ROE (TTM)

15.35%

ROA (TTM)

12.88%

Asset Turnover

0.44x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+116.24%

EPS CAGR 3Y

+51.87%

EBITDA YoY

—

MomentumView details →

1D Return

−3.21%

YTD Return

−3.10%

1Y Return

−3.41%

RSI (14)

32.2

vs 50D SMA

−14.47%

vs 200D SMA

−4.28%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

5.12x

Quick Ratio

4.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$7.32

EPS Surprise

16.75%

Beats (12Q)

5/12

Next Q EPS Est

$8.11

Avg Surprise (4Q)

49.22%

Rev Surprise

72.75%

Financials snapshotView financials →

Revenue (TTM)

7.76B

Net Income (TTM)

2.30B

Op. CF (TTM)

—

Next earningsOct 22, 2026 →

Latest newsMore news →

ARGENX SE announced that it will host a conference call and audio webcast on October 22, 2026, to discuss its third-quarter financial results and provide a business update.2d ago

ARGENX SE shares fell 12%.7d ago

Similar companies

艾力斯688578.SH Amicogen, Inc.092040.KQ Asymchem Laboratories (Tianjin) Co., Ltd.06821.HK Encell Co. Ltd.456070.KQ Pharmaron Beijing Co., Ltd.03759.HK GeneOne Life Science, Inc.011000.KS Find similar companies →

Latest newsMore news →

ARGENX SE announced that it will host a conference call and audio webcast on October 22, 2026, to discuss its third-quarter financial results and provide a business update.2d ago ARGENX SE shares fell 12%.7d ago SueWallSt notified investors of a pending investigation into ARGENX SE.8d ago